Unknown

Dataset Information

0

Acellular Pertussis Vaccine Inhibits Bordetella pertussis Clearance from the Nasal Mucosa of Mice.


ABSTRACT: Bordetella pertussis whole-cell vaccines (wP) caused a spectacular drop of global pertussis incidence, but since the replacement of wP with acellular pertussis vaccines (aP), pertussis has resurged in developed countries within 7 to 12 years of the change from wP to aP. In the mouse infection model, we examined whether addition of further protective antigens into the aP vaccine, such as type 2 and type 3 fimbriae (FIM2/3) with outer membrane lipooligosaccharide (LOS) and/or of the adenylate cyclase toxoid (dACT), which elicits antibodies neutralizing the CyaA toxin, could enhance the capacity of the aP vaccine to prevent colonization of the nasal mucosa by B. pertussis. The addition of the toxoid and of the opsonizing antibody-inducing agglutinogens modestly enhanced the already high capacity of intraperitoneally-administered aP vaccine to elicit sterilizing immunity, protecting mouse lungs from B. pertussis infection. At the same time, irrespective of FIM2/3 with LOS and dACT addition, the aP vaccination ablated the natural capacity of BALB/c mice to clear B. pertussis infection from the nasal cavity. While wP or sham-vaccinated animals cleared the nasal infection with similar kinetics within 7 weeks, administration of the aP vaccine promoted persistent colonization of mouse nasal mucosa by B. pertussis.

SUBMITTER: Holubova J 

PROVIDER: S-EPMC7711433 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Acellular Pertussis Vaccine Inhibits <i>Bordetella pertussis</i> Clearance from the Nasal Mucosa of Mice.

Holubová Jana J   Staněk Ondřej O   Brázdilová Ludmila L   Mašín Jiří J   Bumba Ladislav L   Gorringe Andrew R AR   Alexander Frances F   Šebo Peter P  

Vaccines 20201119 4


<i>Bordetella pertussis</i> whole-cell vaccines (wP) caused a spectacular drop of global pertussis incidence, but since the replacement of wP with acellular pertussis vaccines (aP), pertussis has resurged in developed countries within 7 to 12 years of the change from wP to aP. In the mouse infection model, we examined whether addition of further protective antigens into the aP vaccine, such as type 2 and type 3 fimbriae (FIM2/3) with outer membrane lipooligosaccharide (LOS) and/or of the adenyla  ...[more]

Similar Datasets

| S-EPMC6776550 | biostudies-literature
| S-EPMC7794405 | biostudies-literature
| S-EPMC10561720 | biostudies-literature
| S-EPMC8097269 | biostudies-literature
| S-EPMC9135841 | biostudies-literature
| S-EPMC10873172 | biostudies-literature
| S-EPMC6558669 | biostudies-literature
| S-EPMC8506493 | biostudies-literature
| S-EPMC6204743 | biostudies-literature
| S-EPMC5994715 | biostudies-literature